24700-10-5

Upstream product

• 3350-78-5 3,3-Dimethylacryloyl chloride 
• 700-13-0 Trimethylhydroquinone 
• 541-47-9 3-Methylbutenoic acid 

Downstream Products

• 161528-14-9 methyl 2,3-dihydro-5-<(4-nitrobenzoyl)oxy>-2,2,4,6,7-pentamethyl-1-benzofuran-3-carboxylate 
• 153490-99-4 3,4-dihydro-2,2,5,7,8-pentamethyl-6-hydroxy-2H-1-benzopyran-4-one 4-nitrobenzoate 

Relevant academic research and scientific papers

Chroman derivatives as lipoxygenase inhibitors

The present invention is concerned with certain novel derivatives of Formula I: wherein X and R1 to R10 are as described in the specification, and where either R5 is OH, —NRdORa or —NRd—NRbRc, or R7 is —NRdORa or —NRd—NRbRc, or C=R7R8 is C=NORa or C=N—NRbRc, which may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They may also be useful in the manufacture of skin care and/or pharmaceutical compositions for the treatment of lipoxygenase mediated disorders.

2,3-Dihydro-1-benzofuran-5-ols as analogues of α-tocopherol that inhibit in vitro and ex vivo lipid autoxidation and protect mice against central nervous system trauma

A series of α-tocopherol analogues was synthesized with potential therapeutic value for such pathological conditions as stroke and trauma. A set of criteria such as the inhibition of in vitro lipid peroxidation, superoxyl radical scavenging, and brain penetration, as measured by ex vivo inhibition of lipid peroxidation, was applied to select the most effective compound. 2,3-Dihydro-2,2,4,6,7-pentamethyl-3-[(4-methylpiperazino)methyl]- 1-benzofuran-5-ol dihydrochloride (22) was selected because of its superior antioxidant properties and better brain penetration. This compound also protected mice against the effects of head injury. The criteria thus turned out to be useful for the characterization of a neuroprotective analogue of α-tocopherol.